At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 181 enrolled
Drug / intervention
Pimavanserin tartrate +1 moredrug
Likely dose
Pimavanserin tartrate 40 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single Center, Double-Blind, Placebo-Controlled Study to Examine the Safety and Efficacy of Pimavanserin for the Treatment of Psychosis in Alzheimer's Disease
In Brief
A Phase 2 clinical trial evaluating Pimavanserin tartrate and Placebo for Alzheimer's Disease Psychosis. Completed, enrolled 181 participants across 1 site.
Detailed Summary
This study will evaluate the safety and efficacy of pimavanserin 40 mg compared to placebo in patients with Alzheimer's disease psychosis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease Psychosis
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedJan 2014
Primary CompletionSep 2016
Study CompletionOct 2016
TodayJul 2026
First PostedJan 14, 2014
Enrollment StartNov 1, 2013
Primary CompletionSep 28, 2016
Study CompletionOct 27, 2016
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 12.5 years ago
Interventions
Pimavanserin tartratedrug
Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
Placebodrug
Placebo, two tablets, once daily by mouth